UHC offers MRI/Ultrasound Fusion Biopsy

UHC is proud to introduce a powerful new MRI solution for targeted biopsy of the prostate.

Through the recent adoption of the UroNav fusion biopsy system, doctors at UHC can offer a truly new biopsy option for many patients with elevated and/or rising PSA levels.

“With one out of every six men being diagnosed in their lifetime, prostate cancer has become the most common form of cancer in American Men,” Grant L. Franklin, Jr., M.D., urologist at UHC Urology, said. “With prostate cancer becoming the most common form of cancer in this population, UHC Urology’s introduction of MRI/Ultrasound fusion biopsy could not have come sooner.”

UroNav fuses pre-biopsy MRI images of the prostate with ultrasound-guided biopsy images in real time, for excellent delineation of the prostate and suspicious lesions. After a patient has undergone a prostate MRI, radiologists utilize DynaCAD for Prostate to quickly visualize and evaluate suspicious lesions.

The UroNav fusion biopsy system uses this critical diagnostic information to provide the urologists with a targeted approach to prostate biopsy. The fusion of MRI and ultrasound images through UroNav gives urologists the ability to offer their patients an alternative to remaining in an uncertain state of diagnosis after a prostate exam.

“This new technology will bring new hope to patients and provide our healthcare provides with the latest innovation in identifying and targeting suspicious prostate lesions,” Dr. Franklin said. “UHC Urology is pleased to offer Targeted MRI/ultrasound biopsy technology to our patients as the new standard in prostate care.”

Please note, the information provided throughout this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and video, on or available through this website is for general information purposes only. If you are experiencing related symptoms, please visit your doctor or call 9-1-1 in an emergency.